View:
X4 Pharmaceuticals, Inc.
61 North Beacon Street, 4th Floor
Boston, MA 02134
July 7, 2021
Via Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jeffrey Gabor
RE: X4 Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-257422
Acceleration Request
Requested Date: July 9, 2021
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-257422) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Friday, July 9, 2021, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Daniel I. Goldberg of Cooley LLP, counsel to the registrant, at (212) 479-6722.
[Signature page follows]
Sincerely,
X4 Pharmaceuticals, Inc.
By: __ /s/Adam S. Mostafa
Adam S. Mostafa
Chief Financial Officer
cc: Paula Ragan, Ph.D., Chief Executive Officer, X4 Pharmaceuticals, Inc.
Derek Meisner, General Counsel, X4 Pharmaceuticals, Inc.
Daniel I. Goldberg, Cooley LLP
Courtney T. Thorne, Cooley LLP